Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Payables (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Payables for 15 consecutive years, with $14.3 million as the latest value for Q4 2025.

  • Quarterly Payables fell 9.24% to $14.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.3 million through Dec 2025, down 9.24% year-over-year, with the annual reading at $10.6 million for FY2025, 16.59% down from the prior year.
  • Payables for Q4 2025 was $14.3 million at Aytu Biopharma, up from $12.3 million in the prior quarter.
  • The five-year high for Payables was $25.1 million in Q1 2023, with the low at $9.4 million in Q3 2021.
  • Average Payables over 5 years is $14.6 million, with a median of $14.7 million recorded in 2022.
  • The sharpest move saw Payables surged 125.3% in 2023, then crashed 51.92% in 2024.
  • Over 5 years, Payables stood at $15.6 million in 2021, then rose by 15.41% to $18.0 million in 2022, then tumbled by 36.15% to $11.5 million in 2023, then soared by 36.63% to $15.7 million in 2024, then decreased by 9.24% to $14.3 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $14.3 million, $12.3 million, and $10.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.